Fig. 6

Kaplan-Meier PFS and OS estimates according to ALCs, CD4 plus CD8 counts, PD-L1 IHC and TMB in cohort B. In patients without oncogene-driven NSCLC (cohort B), post-treatment low ALCs (< 800 cells/μL, red) were associated with statistically significant shorter PFS (A) but not OS (B) compared to high ALCs (≥800 cells/μL, blue). Post-treatment low CD4 plus CD8 cell counts (< 500 cells/μL, red) were associated with shorter PFS and OS compared to high CD4 plus CD8 cell counts (≥500 cells/μL, blue) (cohort B) (A and B), respectively. Patients with NSCLC expressing PD-L1 IHC < 50% had shorter PFS and shorter OS compared to those patients with NSCLC expressing PD-L1 IHC ≥50% (C). Patients with NSCLC expressing TMB ≥10 Mut/Mb had shorter PFS but not OS compared to those patients with NSCLC expressing TMB < 10 Mut/Mb (D). Tick marks indicate censored data. Groups were compared using the log-rank test. P < 0.05 for statistical significance